Results 1 to 10 of about 3,376,946 (257)

An Updated Overview of the Magnetic Resonance Imaging of Brain Iron in Movement Disorders

Behavioural Neurology, 2022
Brain iron load is one of the most important neuropathological hallmarks in movement disorders. Specifically, the iron provides most of the paramagnetic metal signals in the brain and its accumulation seems to play a key role, although not completely ...
Nicola Tambasco, Pasquale Nigro, Andrea Chiappiniello, Federico Paolini Paoletti, Sara Scialpi, Simone Simoni, Pietro Chiarini, Lucilla Parnetti   +7 more
doaj   +1 more source

A single centre prospective study of three device-assisted therapies for Parkinson’s disease

npj Parkinson's Disease, 2023
Comparative studies assessing outcomes with the three device-assisted therapies could help to individualise treatment for patients living with Parkinson’s disease.
Hugo Morales-Briceño, Ainhi D. Ha, Han-Lin Chiang, Yicheng Tai, Florence C. F. Chang, David S. Tsui, Jane Griffith, Donna Galea, Samuel D. Kim, Belinda Cruse, Neil Mahant, Victor S. C. Fung   +11 more
doaj   +1 more source

A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson’s disease

npj Parkinson's Disease, 2021
There is great heterogeneity in both the clinical presentation and rate of disease progression among patients with Parkinson’s disease (PD). This can pose prognostic difficulties in a clinical setting, and a greater understanding of the risk factors that
Camilla Christina Pedersen, Johannes Lange, Marthe Gurine Gunnarsdatter Førland, Angus D. Macleod, Guido Alves, Jodi Maple-Grødem   +5 more
doaj   +1 more source

The impact of recurrent Covid-19 waves on patients with Functional Movement Disorders: A follow-up study

Clinical Parkinsonism & Related Disorders, 2022
Background: Functional Movement Disorders (FMDs) might exacerbate in stressful conditions. As the global health emergency due to Covid-19 rise and multiple waves hit the Italian population, the recurrent severe restrictions’ periods imposed could ...
Angela Sandri, Ilaria A. Di Vico, Marianna Riello, Angela Marotta, Michele Tinazzi   +4 more
doaj   +1 more source

Validation and assessment of preanalytical factors of a fluorometric in vitro assay for glucocerebrosidase activity in human cerebrospinal fluid

Scientific Reports, 2020
Lysosomal dysfunction is an emerging feature in the pathology of Parkinson’s disease and Dementia with Lewy bodies. Mutations in the GBA gene, encoding the enzyme Glucocerebrosidase (GCase), have been identified as a genetic risk factor for these ...
Linn Oftedal, Jodi Maple-Grødem, Marthe Gurine Gunnarsdatter Førland, Guido Alves, Johannes Lange   +4 more
doaj   +1 more source

Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers

npj Parkinson's Disease, 2022
Non-manifesting carriers (NMCs) of Parkinson’s disease (PD)-related mutations such as LRRK2 and GBA are at an increased risk for developing PD. Dopamine transporter (DaT)-spectral positron emission computed tomography is widely used for capturing ...
Amgad Droby, Moran Artzi, Hedva Lerman, R. Matthew Hutchison, Dafna Ben Bashat, Nurit Omer, Tanya Gurevich, Avi Orr-Urtreger, Batsheva Cohen, Jesse M. Cedarbaum, Einat Even Sapir, Nir Giladi, Anat Mirelman, Avner Thaler   +13 more
doaj   +1 more source

Sexual Dysfunctions in Parkinson’s Disease and Their Influence on Partnership—Data of the PRISM Study

Brain Sciences, 2022
Background: Sexual dysfunctions (SD) are common but underreported in Parkinson’s disease (PD) and have negative impacts on the quality of life (QoL) and partnership.
Thomas Kinateder, Daniela Marinho, Doreen Gruber, Laura Hatzler, Georg Ebersbach, Florin Gandor   +5 more
doaj   +1 more source

Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) among Patients at a Movement Disorders Center

Geriatrics, 2020
It is not established whether SARS-CoV-2 (COVID-19) patients with movement disorders, are at greater risk for more serious outcomes than the larger COVID-19 population beyond the susceptibility associated with greater age.
Joy Antonelle de Marcaida, Jeffrey Lahrmann, Duarte Machado, Lawrence Bluth, Michelle Dagostine, Maria Moro-de Casillas, Elena Bortan, Sulada Kanchana, Mark Alberts   +8 more
doaj   +1 more source

Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study

Brain Sciences, 2019
Background: Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson’s Disease (PD) patients with a potential benefit on non-motor symptoms (NMS).
Gloria Martí-Andrés, Rayco Jiménez-Bolaños, José Matias Arbelo-González, Javier Pagonabarraga, Carmen Duran-Herrera, Rafael Valenti-Azcarate, Mª Rosario Luquin   +6 more
doaj   +1 more source

The impact and feasibility of a brief, virtual, educational intervention for home healthcare professionals on Parkinson’s Disease and Related Disorders: pilot study of I SEE PD Home

BMC Medical Education, 2022
Background Individuals with advanced Parkinson’s Disease (PD) and Parkinson-related disorders (PRD) are frequently referred for home allied therapies and nursing care, yet home healthcare professionals have limited training in PD/PRD.
Serena P. Hess, Melissa Levin, Faizan Akram, Katheryn Woo, Lauren Andersen, Kristie Trenkle, Patricia Brown, Bichun Ouyang, Jori E. Fleisher   +8 more
doaj   +1 more source